Simplify Logo

Full-Time

QC STAT Associate

Posted on 9/16/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Entry, Junior

Devens, MA, USA

Site-essential role requires 100% of shifts onsite.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • Knowledge of science generally attained through studies resulting in a BS degree, preferably in Chemistry, Molecular Biology, or related discipline.
  • A minimum of 0-2 years of experience in a Biologics QC laboratory or related biopharmaceutical cGLP or cGMP lab.
  • Experience in analytical test methods such as UV/Vis, HPLC, TOC, and protein purification highly preferred.
  • Knowledge of lab software applications (e.g., LIMS, ELN (LES/SmartLab), Empower) preferred.
  • Excellent manual dexterity including proficiency in aseptic techniques desired.
  • High attention to detail with strong general laboratory and good organizational skills.
  • Demonstrated ability to work independently as well as part of a team, to complete assignments within defined time constraints.
  • Ability to interpret and apply cGMPs, USP, regulatory requirements and industry best practices.
  • Demonstrates problem solving and analytical thinking skills.
Responsibilities
  • Performs routine testing and data review of in-process and batch release samples of Bulk Drug Substance in a cGMP compliant environment.
  • Performs routine assays such as UV-VIS Spectrometry, Titer, utility testing, personnel and environmental monitoring, Total Organic Carbon testing, and more complex assays including various HPLC methodologies (e.g., sialic acid).
  • Performs broad range of troubleshooting techniques and leads such within area of expertise.
  • May write and revise SOPs for managerial review and approval.
  • May train less experienced analysts on basic and some more complex test methods.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs, providing affordable alternatives that maintain the same quality and safety standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while adhering to sustainability and corporate responsibility principles.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's involvement in Nobel Prize-winning immunology research underscores its leadership in groundbreaking scientific advancements.
  • The robust pipeline of molecular glues and other innovative therapies promises significant revenue growth and market expansion.
  • Recognition in the Dow Jones Sustainability Index North America highlights BMS's commitment to corporate responsibility and sustainability, enhancing its reputation and stakeholder trust.

What critics are saying

  • The termination of strategic collaborations, such as with Eisai, could impact BMS's ability to bring new therapies to market efficiently.
  • Ongoing layoffs and restructuring efforts may lead to decreased employee morale and potential disruptions in operations.

What makes Bristol-Myers Squibb unique

  • Bristol Myers Squibb's dual focus on innovative and generic medicines allows it to cater to a broad spectrum of healthcare needs, unlike competitors who may focus solely on one area.
  • Their commitment to sustainability and ESG goals sets them apart in the biopharmaceutical industry, appealing to socially conscious investors and stakeholders.
  • BMS's extensive R&D investment in oncology, immunology, and cardiovascular diseases positions it as a leader in developing cutting-edge treatments for serious diseases.
INACTIVE